Draft:Formation Bio

Submission declined on 14 August 2026 by Sulfurboy (talk). This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for organizations and companies. The draft requires multiple published secondary sources that: provide significant coverage: discuss the subject in detail, excluding routine coverage like product launches, staff appointments, or financial reports and listings in databases or listicles; are reliable: from reputable outlets with editorial oversight; are independent: not connected to the subject, such as press releases, the subject's own website, or sponsored content. Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia. This draft is not written from a neutral point of view. Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove: promotional language: see Words to watch; personal commentary: opinions or direct addresses to the reader; informal language. Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. If you would like to continue working on the submission, click on the "Edit" tab at the top of the window. If you have not resolved the issues listed above, your draft will be declined again and potentially deleted. If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors. Please do not remove reviewer comments or this notice until the submission is accepted. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Easy tools: Citation bot (help) | Advanced: Fix bare URLs Declined by Sulfurboy 8 days ago. Last edited by Sulfurboy 8 days ago. Reviewer: Inform author. Resubmit Please note that if the issues are not fixed, the draft will be declined again.

• Comment: WP:ORGTRIV and WP:CHURN does very little to denote notability Sulfurboy (talk) 20:21, 14 August 2026 (UTC)

Formation Bio is a biotechnology company that applies artificial intelligence to the acquisition and development of clinical-stage drug candidates. Founded in 2016 and headquartered in New York City, the company acquires drug candidates and uses AI to advance them through clinical trials.^[1]

Formation Bio was founded in 2016 by Benjamine Liu and Linhao Zhang.^[2][3][4] The company originated from work Liu conducted as a computational biologist at the University of Oxford, where he studied machine learning applications for identifying therapeutic candidates for neurodegenerative diseases.^[5] Liu has cited the limited capacity of pharmaceutical companies to advance drug candidates through clinical development as a basis for the company's founding.^[5][4][6][1]

Initially operating as TrialSpark, the company developed technology to streamline clinical trial execution in support of its long-term goal of building a drug development organization.^[6] The company later rebranded as Formation Bio as it expanded its internal pipeline through in-licensing and acquisition of clinical-stage programs. ^[7][8][9]

In 2019, Liu and Zhang partnered with former Novartis chief executive Joseph Jimenez to establish Aditum Bio, a venture firm that acquired drug candidates and developed them through separate companies, with Formation Bio as a minority investor.^[1] Formation Bio held a minority stake in Versanis Bio, a company founded by Aditum Bio in 2021, which was acquired by Eli Lilly in 2023 for up to $1.925 billion.^[10][11]

In June 2025, Formation Bio licensed gusacitinib, a Phase 3-stage oral dual JAK/SYK inhibitor, to Sanofi in a deal worth up to €545 million in upfront and milestone payments.^[12]

The company has been listed in the 2025 CNBC Disruptor 50,^[4] Fierce Biotech’s 2025 Fierce 15,^[13] BioSpace’s 2025 40 Under 40,^[14][15] and received the 2024 Endpoints 11 award.^[16]

Formation Bio partners with, acquires, and in-licenses clinical-stage drug candidates from pharmaceutical companies, biotechnology firms, and research institutions. The company focuses on advancing these assets through clinical proof of concept and later stages of development.^[17][3] Formation Bio typically acquires drug candidates in early-stage clinical development — typically those that have not yet completed Phase 2 clinical trials — and develops them in-house leveraging its AI platform. After reaching clinical milestones, the company outlicenses or partners drug assets for further development and commercialization.^[4][1]

Formation Bio uses a “hub-and-spoke” model in which each asset is placed into a separate subsidiary or “NewCo”, which serves as a dedicated funding and operational vehicle for the specific program.

The company’s leadership and advisory team comprises individuals from both the AI and pharma industries.

Formation Bio, OpenAI and Sanofi announced a collaboration in May 2024 to develop custom AI models for use in drug development.^[18][19][20] In November 2024, the first outcome of the collaboration between the three companies was launched, an AI tool to speed patient recruitment for clinical trials named Muse.^[19][4]

Since its founding, the company has raised over $600 million from investors including Sequoia Capital, Michael Moritz, Thrive Capital, and Andreessen Horowitz.^[4] A Series D financing round of approximately $372 million was announced in June 2024 to support expansion of the company’s development pipeline and AI technology platform.^[8][9][19]

Formation Bio acquires and develops clinical stage programs across a wide range of therapeutic areas.^[8] The company’s clinical pipeline can be found here.